Previous 10 | Next 10 |
NuZee ( NUZE ) -24% on pricing $3.4M stock offering . Reata Pharmaceuticals ( RETA ) -20% on Q2 earnings release . Palantir Technologies ( PLTR ) -14% on Q2 earnings release . Digital World Acquisition ( DWACW ) -10% . Cognit...
Gainers: Allied Healthcare Products ( AHPI ) +30% . Progyny ( PGNY ) +28% . Kazia Therapeutics ( KZIA ) +21% . Selecta Biosciences ( SELB ) +18% . Sensus Healthcare ( SRTS ) +17% . Losers: Quoin Pharmaceuticals ( QNRX...
An analysis of biomarker data from Cognition Therapeutics' ( NASDAQ: CGTX ) Alzheimer's disease candidate CT1812 indicate the oral once-daily treatment supports a synaptoprotective mechanism of action and has a role in normalizing cellular processes. Proteomic analyses...
Hyzon Motors ( HYZN ) -36% after disclosing operational inefficiencies, financial issues . Helius Medical Technologies ( HSDT ) -30% . Quoin Pharmaceuticals ( QNRX ) -23% . Chembio Diagnostics ( CEMI ) -18% on Q2 earnings release . ...
NEW YORK, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics , Inc. (NASDAQ: CGTX) announced that Mary Hamby, Ph.D. , vice president of research, presented results at the at Alzheimer’s Association International Conference (AAIC) of proteomic analysi...
PURCHASE, N.Y., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the ...
Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports and conference presentat...
- Analyses Demonstrate CT1812 Impact on Alzheimer’s Disease Processes - NEW YORK, July 19, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics , Inc. (NASDAQ: CGTX) will be in attendance at the 2022 Alzheimer’s Association International Conference (...
Gainers: Allena Pharmaceuticals ( ALNA ) +191% . Brickell Biotech ( BBI ) +78% . Decibel Therapeutics ( DBTX ) +35% . Cognition Therapeutics ( CGTX ) +26% . Akouos ( AKUS ) +20% . Fujian Blue Hat Interactive Entertainment Tec...
Cognition Therapeutics (NASDAQ:CGTX) stock rose ~6% on June 23 after the company said the first patient was dosed in a phase 2 trial of oral drug CT1812 to treat patients with dementia with Lewy bodies (DLB). The company plans to enroll 120 adults between 50 and 80 years of age with a DL...
News, Short Squeeze, Breakout and More Instantly...
Cognition Therapeutics Inc. Company Name:
CGTX Stock Symbol:
NASDAQ Market:
Cognition Therapeutics Inc. Website:
2024-07-29 17:15:02 ET Cantor Fitzgerald analyst issues NEUTRAL recommendation for CGTX on July 29, 2024 04:08PM ET. CGTX was trading at $1.33 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 3 - Buy recom...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 1.3% to $111.59 on volume of 240,827,673 shares Lipella Pharmaceuticals Inc. (LIPO) rose 122.5% to $0.8992 on volume of 193,926,302 shares PROSHARES TRUST (SQQQ) fell 0.5% to $9.05 on volume of 150,372,371...
- CT1812 Treatment Showed ~40% Mean Improvement in Cognitive Measures vs Placebo - - Consistent Positive Changes Across Cognitive and Functional Measures - - Favorable Safety Profile with Most Treatment-Related Adverse Events Mild or Moderate - - Significant Changes in Neurofila...